[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_custom_heading text=”Message from Team IMA Chennai Kauvery Alwarpet Branch” font_container=”tag:h2|text_align:center|color:%239a286d” google_fonts=”font_family:PT%20Sans%3Aregular%2Citalic%2C700%2C700italic|font_style:700%20bold%20regular%3A700%3Anormal”][vc_row_inner css=”.vc_custom_1618206149394{border-radius: 5px !important;}”][vc_column_inner width=”1\/3″][vc_column_text]![\"\"](\"https:\/\/www.kauveryhospital.com\/ima-journal\/wp-content\/uploads\/2023\/09\/dr.sivaram-150x150.jpg\")
<\/p>\n
Dear IMA colleagues,<\/p>\n
Happy New Year 2026 and Happy Pongal from Kauvery IMA! Wishing you joy, prosperity, and good health this festive season.<\/p>\n
The TIMACON 2025, was well organised at Karaikudi and our congratulations and best wishes to new state president Dr Sridhar and the state secretary Dr Thiravia Mohan.<\/p>\n
Our Brach was awarded with 10 awards, and I extend our thanks to the awards committee and our members who made it possible<\/p>\n
I’m excited to share that IMA journals keep empowering doctors with the latest medical knowledge, driving continuous learning and excellence in healthcare. Here’s to another year of growth and service!<\/p>\n
Yours in IMA service,<\/em> Dear IMA members,<\/p>\n As we step into 2026, Kauvery Hospital, Alwarpet extends heartfelt wishes for a happy, healthy year ahead and a joyous Pongal!<\/p>\n IMA Journal shares medical articles and case reports as part of CME drive. Sharing knowledge with you!<\/p>\n Yours in IMA service,<\/em> Dear friends,<\/p>\n Happy Pongal! 🌅 Wishing you all a joyous and prosperous new year! 😊<\/p>\n I’m thrilled to share this month’s IMA Journal with you! 🎉 Great academic work is happening across departments at our hospital, and we’re excited to share some highlights. Thanks to the editorial and marketing teams, IMA Journal is a great platform to share knowledge with colleagues. Your feedback and suggestions are welcome!<\/p>\n Long live IMA.<\/p>\n With regards<\/em> Read Full Article<\/a>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”blog-col” css=”.vc_custom_1617009566389{border-radius: 5px !important;}”][vc_column_inner width=”1\/3″][vc_single_image image=”10826″ img_size=”large”][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_custom_heading text=”MRI Spectrum of Atypical PRES in a Juvenile Nephronophthisis Patient on Hemodialysis” font_container=”tag:h2|text_align:left|color:%239a286d” google_fonts=”font_family:PT%20Sans%3Aregular%2Citalic%2C700%2C700italic|font_style:700%20bold%20regular%3A700%3Anormal”][vc_column_text]Introduction:<\/b><\/strong><\/p>\n Posterior Reversible Encephalopathy Syndrome (PRES) is a neurotoxic clinico-radiological condition characterized by acute neurological symptoms such as seizures, altered mental status, visual disturbances, and headache, accompanied by vasogenic edema predominantly affecting the parieto-occipital regions. Although initially described as posterior and reversible, PRES is now recognized to present with a wide anatomical spectrum, including atypical involvement of the frontal lobes, temporal lobes, deep gray nuclei, cerebellum, and brainstem. Conditions associated with hypertension, renal failure, immunosuppressive therapy, and fluid\u2013electrolyte imbalance predispose to the syndrome by disrupting cerebral autoregulation and causing endothelial injury.<\/p>\n Read Full Article<\/a>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”blog-col” css=”.vc_custom_1617009566389{border-radius: 5px !important;}”][vc_column_inner width=”1\/3″][vc_single_image image=”10825″ img_size=”large”][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_custom_heading text=”Pneumocystis jirovecii Pneumonia in the Intensive Care Unit: A Case Series” font_container=”tag:h2|text_align:left|color:%239a286d” google_fonts=”font_family:PT%20Sans%3Aregular%2Citalic%2C700%2C700italic|font_style:700%20bold%20regular%3A700%3Anormal”][vc_column_text]Abstract:<\/strong><\/p>\n Pneumocystis jirovecii pneumonia (PCP) remains a significant cause of respiratory failure in immunocompromised hosts. While historically associated with HIV infection, PCP is increasingly recognized in non-HIV immunosuppressed populations, often with distinct clinical courses. We report two critically ill PCP patients\u2014one HIV-positive and one HIV-negative\u2014highlighting differences in presentation, diagnosis, management, and outcomes<\/p>\n Read Full Article<\/a>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”blog-col” css=”.vc_custom_1617009566389{border-radius: 5px !important;}”][vc_column_inner width=”1\/3″][vc_single_image image=”10837″ img_size=”large”][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_custom_heading text=”Ultrasound-Guided Erector Spinae Plane Block for Pain Management in Hypertriglyceridemia-Induced Acute Pancreatitis: A Case Report” font_container=”tag:h2|text_align:left|color:%239a286d” google_fonts=”font_family:PT%20Sans%3Aregular%2Citalic%2C700%2C700italic|font_style:700%20bold%20regular%3A700%3Anormal”][vc_column_text]<\/p>\n Abstract<\/strong><\/p>\n Pain associated with acute pancreatitis is often severe and difficult to manage, traditionally requiring opioid-based analgesia. Opioids, however, are associated with adverse effects such as nausea, vomiting, ileus, sedation, and respiratory depression. Recent evidence suggests that ultrasound-guided erector spinae plane block (ESPB) provides effective visceral analgesia with reduced opioid requirement in hepatopancreaticobiliary pain. We report a case of recurrent acute pancreatitis secondary to hypertriglyceridemia in a 40-year-old woman, where ESPB was used as part of multimodal analgesia, resulting in significant pain relief and improved patient comfort. This case supports the role of ESPB as a safe and effective analgesic modality in acute pancreatitis.<\/p>\n
\nDr S Sivaram Kannan<\/strong>
\nPresident[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”blog-col1″ width=”1\/3″][vc_column_text]![\"\"](\"https:\/\/www.kauveryhospital.com\/ima-journal\/wp-content\/uploads\/2023\/05\/Dr-B-R-150x150.jpg\")
<\/p>\n
\nDr. Bhuvaneshwari Rajendran<\/strong>
\nSecretary[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=”blog-col1″ width=”1\/3″][vc_column_text]![\"\"](\"https:\/\/www.kauveryhospital.com\/ima-journal\/wp-content\/uploads\/2023\/05\/Dr.-R.-B-251x300.jpg\")
<\/p>\n
\nDr. R. Balasubramaniyam<\/strong>
\nEditor[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner][vc_empty_space][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”blog-col” css=”.vc_custom_1617009566389{border-radius: 5px !important;}”][vc_column_inner width=”1\/3″][vc_single_image image=”10827″ img_size=”large”][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_custom_heading text=”An Unintended Pulmonary Complication of Dasatinib in Chronic Myeloid Leukemia” font_container=”tag:h2|text_align:left|color:%239a286d” google_fonts=”font_family:PT%20Sans%3Aregular%2Citalic%2C700%2C700italic|font_style:700%20bold%20regular%3A700%3Anormal”][vc_column_text]Chronic myeloid Leukemia is a myeloproliferative neoplasm characterized by the BCR- ABL1 fusion gene resulting from the Philadelphia chromosome translocation. Tyrosine kinase inhibitors have dramatically improved outcomes in CML. Dasatinib, a second-generation TKI has shown superior responses compared to imatinib. However, dasatinib is associated with unique adverse effects, most notably pleural effusion, which can occur at any time during therapy and may impact treatment continuity. This case highlights the importance of vigilance for pulmonary adverse effects during dasatinib therapy and discusses the possible mechanisms, risk factors, and management strategies.<\/p>\n